Year: 2019
Type: review
Abstract: Non-alcoholic fatty liver disease (NAFLD) affects one-third of the population worldwide, of which a substantial number of patients suffer from non-alcoholic steatohepatitis (NASH). NASH is a severe condition characterized by steatosis and concomitant liver inflammation and fibrosis, for which no drug is yet available. NAFLD is also generally conceived as the hepatic manifestation of the metabolic syndrome. Consequently, well-established drugs that are indicated for the treatment of type 2 diabetes and hyperlipidemia are thought to exert effects that alleviate the pathological features of NASH. One class of these drugs targets peroxisome proliferator-activated receptors (PPARs), which are nuclear receptors that play a regulatory role in lipid metabolism and inflammation. Therefore, PPARs are now also being investigated as potential anti-NASH druggable targets. In this paper, we review the mechanisms of action and physiological functions of PPARs and discuss the position of the different PPAR agonists in the therapeutic landscape of NASH. We particularly focus on the PPAR agonists currently under evaluation in clinical phase II and III trials. Preclinical strategies and how refinement and optimization may improve PPAR-targeted anti-NASH drug testing are also discussed. Finally, potential caveats related to PPAR agonism in anti-NASH therapy are stipulated.
Source: Cells
DOI: 10.3390/cells9010037
Institution: Vrije Universiteit Brussel
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,824
Funder: Fonds Wetenschappelijk Onderzoek
Awards: Investigating the impact of PNPLA3 genetic polymorphism on the development and treatment of non-alcoholic steatohepatitis (NASH): an in vitro study using human stem cell-derived hepatic cells., G1695326789, Development and characterization of a human skin stem cell-derived in vitro liver model for anti-NASH drug screening., Improve the reprogramming of human adult skin-derived fibroblasts into functional hepatocytes by directed evolution of hepatocyte nuclear factors
OpenAlex ID: W2994912142
